JP2014506259A5 - - Google Patents

Download PDF

Info

Publication number
JP2014506259A5
JP2014506259A5 JP2013548861A JP2013548861A JP2014506259A5 JP 2014506259 A5 JP2014506259 A5 JP 2014506259A5 JP 2013548861 A JP2013548861 A JP 2013548861A JP 2013548861 A JP2013548861 A JP 2013548861A JP 2014506259 A5 JP2014506259 A5 JP 2014506259A5
Authority
JP
Japan
Prior art keywords
seq
cdr
ligand
antibody
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013548861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506259A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/050633 external-priority patent/WO2012098113A1/en
Publication of JP2014506259A publication Critical patent/JP2014506259A/ja
Publication of JP2014506259A5 publication Critical patent/JP2014506259A5/ja
Withdrawn legal-status Critical Current

Links

JP2013548861A 2011-01-17 2012-01-17 Il−21リガンド Withdrawn JP2014506259A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
EP11151073 2011-01-17
EP11151073.1 2011-01-17
US201161434989P 2011-01-21 2011-01-21
US61/434,989 2011-01-21
EP11168328.0 2011-05-31
EP11168328 2011-05-31
US201161493002P 2011-06-03 2011-06-03
US61/493,002 2011-06-03
EP11187212.3 2011-10-31
EP11187212 2011-10-31
PCT/EP2012/050633 WO2012098113A1 (en) 2011-01-17 2012-01-17 Il-21 ligands

Publications (2)

Publication Number Publication Date
JP2014506259A JP2014506259A (ja) 2014-03-13
JP2014506259A5 true JP2014506259A5 (enExample) 2015-03-05

Family

ID=46515179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013548861A Withdrawn JP2014506259A (ja) 2011-01-17 2012-01-17 Il−21リガンド

Country Status (5)

Country Link
US (1) US20130323259A1 (enExample)
EP (1) EP2665750A1 (enExample)
JP (1) JP2014506259A (enExample)
CN (1) CN103443124A (enExample)
WO (1) WO2012098113A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122413A1 (en) 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
EP2746293A1 (en) 2012-12-21 2014-06-25 Novo Nordisk A/S Anti-IL21 antibodies for use in the treatment of cardiovascular diseases
US20140178395A1 (en) 2012-12-21 2014-06-26 Novo Nordisk A/S Treatment of nephropathy
US20160347833A1 (en) * 2014-02-07 2016-12-01 Novo Nordisk A/S Antibody process
AR099625A1 (es) 2014-03-21 2016-08-03 Lilly Co Eli Anticuerpos de il-21
JP6672175B2 (ja) 2014-05-07 2020-03-25 ノヴォ ノルディスク アー/エス Glp−1及び抗il−21を使用した1型糖尿病の治療
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
EP3304079B1 (en) 2015-06-03 2020-06-03 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
WO2018213297A1 (en) 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2333772T3 (es) 1999-12-23 2010-03-01 Genentech, Inc. Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas.
SG177012A1 (en) * 2002-05-20 2012-01-30 Abmaxis Inc Generation and selection of protein library in silico
DK1575517T3 (da) * 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
US20070122413A1 (en) * 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
WO2007071061A1 (en) * 2005-12-23 2007-06-28 Viventia Biotech Inc. Methods for generating and screening fusion protein libraries and uses thereof
WO2009047360A1 (en) * 2007-10-11 2009-04-16 Novo Nordisk A/S Il-21 antibodies
EP2217268B1 (en) 2007-12-07 2016-05-04 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
WO2009132821A1 (en) * 2008-04-28 2009-11-05 Giuliani International Limited Interleukin (il-21) binding proteins and methods of making and using same
AR073538A1 (es) * 2008-09-03 2010-11-17 Genentech Inc Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
HUE028021T2 (en) * 2009-04-29 2016-11-28 Janssen Biotech Inc Pen-like receptor antagonists

Similar Documents

Publication Publication Date Title
JP2019528240A5 (enExample)
JP2014526898A5 (enExample)
HRP20211343T1 (hr) Protutijela protiv dkk-1
HRP20210170T1 (hr) Protutijela protiv b7-h3 i konjugati protutijela s lijekom
JP2016196468A5 (enExample)
JP2015532292A5 (enExample)
JP2016502515A5 (enExample)
JP2018507220A5 (enExample)
JP2014502955A5 (enExample)
NZ608206A (en) Antibodies that bind myostatin, compositions and methods
MY190771A (en) Anti-pd-l1 antibodies and uses thereof
JP2018508483A5 (enExample)
JP2011046732A5 (enExample)
HRP20201022T1 (hr) Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
JP2015514110A5 (enExample)
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
ME02533B (me) BISPECIFIČNA ANTITELA PROTIV CD3-EPSILON l BCMA
JP2016538830A5 (enExample)
JP2013538057A5 (enExample)
JP2015502138A5 (enExample)
JP2016512551A5 (enExample)
RU2016129517A (ru) Биспецифические антитела к her2 и способы применения
JP2011514150A5 (enExample)
JP2017515815A5 (enExample)
JP2010526028A5 (enExample)